Department of Pharmaceutical Sciences, Temple University School of Pharmacy, Philadelphia, Pennsylvania 19140, USA.
Adv Exp Med Biol. 2010;678:70-6. doi: 10.1007/978-1-4419-6306-2_10.
The chemotherapy-related cognitive impairment (chemo fog/chemo brain) that is reported by many cancer patients is supported to varying degrees primarily by evidence from prospective and retrospective clinical studies. However, the inherent difficulty in conducting such trials (including ethical issues of placebo-controlled designs), the fact that the cognitive impairment is characteristically subtle and that the patients might be able to compensate for their deficits during testing, gives rise to questions about the degree and the extent of the problem-and indeed even if there is a problem. Neuroimaging techniques might offer additional insight. This chapter is a succinct summary of a more expanded review of the relatively few such studies.
许多癌症患者报告的化疗相关认知障碍（化疗雾/化疗脑）主要得到前瞻性和回顾性临床研究的不同程度的支持。然而，进行此类试验存在固有的困难（包括安慰剂对照设计的伦理问题），认知障碍的特征是微妙的，患者在测试过程中可能能够弥补其缺陷，这引发了关于问题的程度和范围的问题，甚至是否存在问题。神经影像学技术可能提供更多的见解。这一章是对相对较少的此类研究进行更广泛审查的简洁总结。
